These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11790263)

  • 1. The ten most commonly asked questions about management of peripheral arterial disease.
    McPhail I; Yacyshyn V
    Cardiol Rev; 2002; 10(1):5-7. PubMed ID: 11790263
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
    Grouse JR; Allan MC; Elam MB
    J Clin Pharmacol; 2002 Dec; 42(12):1291-8. PubMed ID: 12463722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of cilostazol and other therapies for intermittent claudication.
    Dawson DL
    Am J Cardiol; 2001 Jun; 87(12A):19D-27D. PubMed ID: 11434896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent claudication: effective medical management of a common circulatory problem.
    Beebe HG
    Am J Cardiol; 2001 Jun; 87(12A):14D-18D. PubMed ID: 11434895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.
    Dawson DL; Cutler BS; Meissner MH; Strandness DE
    Circulation; 1998 Aug; 98(7):678-86. PubMed ID: 9715861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
    Money SR; Herd JA; Isaacsohn JL; Davidson M; Cutler B; Heckman J; Forbes WP
    J Vasc Surg; 1998 Feb; 27(2):267-74; discussion 274-5. PubMed ID: 9510281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.
    Beebe HG; Dawson DL; Cutler BS; Herd JA; Strandness DE; Bortey EB; Forbes WP
    Arch Intern Med; 1999 Sep; 159(17):2041-50. PubMed ID: 10510990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of intermittent claudication: cilostazol.
    Collins P; Brittenden J
    Hosp Med; 2004 Aug; 65(8):466-70. PubMed ID: 15330347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilostazol for Intermittent Claudication Caused by Peripheral Artery Disease.
    Lauters R; Wilkin D
    Am Fam Physician; 2022 Apr; 105(4):366-367. PubMed ID: 35426633
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cilostazol is effective and safe option for the treatment of intermittent claudication. Results of the NOCLAUD study].
    Farkas K; Járai Z; Kolossváry E
    Orv Hetil; 2017 Jan; 158(4):123-128. PubMed ID: 28116935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.
    Meng Y; Squires H; Stevens JW; Simpson E; Harnan S; Thomas S; Michaels J; Stansby G; O'Donnell ME
    Angiology; 2014 Mar; 65(3):190-7. PubMed ID: 23378195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cilostazol and peripheral arterial disease.
    Pearce L; Ghosh J; Counsell A; Serracino-Inglott F
    Expert Opin Pharmacother; 2008 Oct; 9(15):2683-90. PubMed ID: 18803454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical management of peripheral arterial disease.
    Creager MA
    Cardiol Rev; 2001; 9(4):238-45. PubMed ID: 11405904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent claudication revisited: the value of medical therapy.
    Hiatt WR
    Arch Intern Med; 1999 Sep; 159(16):1955-6. PubMed ID: 10493329
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.
    Guest JF; Davie AM; Clegg JP
    Curr Med Res Opin; 2005 Jun; 21(6):817-26. PubMed ID: 15969881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.
    Smith JA
    Clin Cardiol; 2002 Mar; 25(3):91-4. PubMed ID: 11892686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication.
    Soga Y; Yokoi H; Kawasaki T; Nakashima H; Tsurugida M; Hikichi Y; Nobuyoshi M
    J Am Coll Cardiol; 2009 Jan; 53(1):48-53. PubMed ID: 19118724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication.
    Lee C; Nelson PR
    Vasc Endovascular Surg; 2014 Apr; 48(3):224-9. PubMed ID: 24399131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of cilostazol (Pletal) in the management of intermittent claudication.
    Bradbury AW
    Int J Clin Pract; 2003 Jun; 57(5):405-9. PubMed ID: 12846346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is intermittent vasculogenic claudication still a nonsurgical disease?
    Taylor SM
    Adv Surg; 2009; 43():53-72. PubMed ID: 19845169
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.